MedWatch

Denmark recommends Lundbeck migraine treatment

The Danish Medicines Council has approved Vyepti, a preventive migraine infusion, for general use in Denmark, to Lundbeck’s excitement.

Photo: Thomas Borberg/Politiken/Ritzau Scanpix

Late Wednesday evening local time, Lundbeck took the final step toward getting Vyepti (eptinezumab) authorized for general use in patients with chronic migraines in Denmark.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs